Google AI for Health Program Selects Five African Startups

By HEOR Staff Writer

October 26, 2023

A New Era for African Health Startups

The 2023 cohort of the Google for Startups Growth Academy: AI for Health program has been announced. The aforementioned selection comprises a total of 30 startup companies. All originating from the regions of Europe, the Middle East, and Africa. Out of the selection, five African firms have been designated, namely mDoc and PharmaRun from Nigeria.

The selection of these firms is based on their utilization of artificial intelligence (AI) in a pioneering manner to address health-related obstacles. They have the potential to enhance healthcare by implementing artificial intelligence (AI)-based solutions. This encompasses a wide range of areas, spanning from the early diagnosis of diseases to the promotion of universal access to information.

 

The Conceptual Framework Underlying the Program

Yuval Passov, the Head of Google for entrepreneurs, articulated his perspective on the potential of African health entrepreneurs utilizing artificial intelligence (AI). The author found Africa’s pioneering attitude in the field of AI for Health to be highly motivating. The chosen startups serve as evidence of the continent’s capacity to create worldwide health solutions. Google’s objective is to align itself with these entities, providing assistance and collaboration as they endeavor to expand and distribute their innovative solutions.

The Google for businesses Growth Academy: AI for Health program aligns with Google’s goal to help businesses grow faster. This program aims to support selected African and international companies. It strives to encourage innovation and healthcare advancements. Ultimately, it seeks to create a lasting positive impact on global welfare.

Reference url

Recent Posts

FDA Endorses Truqap Prostate Cancer Therapy for PTEN-Deficient Cases

By HEOR Staff Writer

May 7, 2026

Truqap Prostate Cancer Therapy gains key backing from FDA advisors for PTEN-deficient metastatic hormone-sensitive prostate cancer, following strong data from the pivotal trial that demonstrated meaningful delays in disease progression. ODAC Backs Targeted Therapy The ...
EUCOPE Pharmaceutical Regulation: Advocating for Innovative SMEs in a Changing Landscape
EUCOPE pharmaceutical regulation shapes how innovative small and medium-sized enterprises navigate Europe's complex approval pathways. Alexander Natz, Secretary General of EUCOPE, explains how the organi...
Unlocking the Benefits of Cardiovascular Health Checks in EU Prevention Strategies
Cardiovascular health checks deliver strong clinical, economic and societal value when delivered as structured, risk-based programmes connected to ongoing care. This approach supports EU cardiovascular prevention strategies by catching cardiometabolic risks early and reducing long-term events. Th...